D-0120
- Generic Name
- D-0120
Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development
• Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report.
• Leading companies in hyperuricemia drug development include LG Chem, Shanton Pharma, InventisBio, Jiangsu HengRui Medicine, and Selecta Biosciences, with treatments spanning oral, intravenous, and subcutaneous administration routes.
• A significant development occurred in December 2024 when Atom Therapeutics partnered with China Medical System Holdings to commercialize lingdolinurad (ABP-671), a novel URAT1 inhibitor for chronic gout and hyperuricemia in China.
Gout Pipeline Shows Promise with Novel Therapies in Clinical Development
• A new report highlights over 30 drugs in the gout pipeline, showcasing potential advancements in treatment strategies and offering hope for patients with this debilitating condition.
• LG Chem's Tigulixostat, a novel xanthine oxidase inhibitor, is in Phase III trials as a potential first-line treatment for gout, demonstrating efficacy in lowering serum uric acid levels.
• Shanton Pharma's SAP-001, a urate transporter inhibitor, is in Phase II development targeting refractory and tophaceous gout, addressing the needs of patients unresponsive to standard therapies.
• InventisBio's D-0120, a selective URAT1 inhibitor, shows promise in Phase II trials with a potentially more potent uric acid-lowering effect and improved safety profile compared to existing treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath